April 25, 2023

‍

‍

‍

Cytek Biosciences Inc (CTKB) is set to replace Cardiovascular Systems Inc (CSII) in the S&P SmallCap 600. The change is expected to be effective from Monday, May 1. This announcement follows Abbott Laboratories' (ABT) acquisition of Cardiovascular Systems in a deal that is expected to close soon, pending final closing conditions.

‍

What is the S&P SmallCap 600?

The S&P SmallCap 600 is an index of small-cap stocks that are considered to be the best representation of the overall small-cap market. It measures the performance of 600 small-cap companies in the United States.

‍

About Cytek Biosciences

Cytek Biosciences is a life sciences company that provides advanced flow cytometry solutions for researchers and clinicians. The company's products help researchers in academic, pharmaceutical, and clinical settings to analyze complex biological systems and improve patient outcomes.

‍

Why is this change significant?

The inclusion of Cytek Biosciences in the S&P SmallCap 600 is significant because it reflects the company's strong financial performance and growth potential. Being part of this index will increase Cytek Biosciences' visibility among investors and could lead to increased demand for its shares.

‍

‍

‍

Members of LevelFields received the alert of this event on April 25, 6:15 PM ET

Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions,and let LevelFields help you become a better trader.